What is Geneseeq?
Geneseeq Technology Inc. operates at the intersection of biotechnology and oncology, providing advanced Next-Generation Sequencing (NGS) solutions. By delivering actionable genomic insights, the company facilitates precise cancer diagnosis, prognosis, and treatment guidance. Their service portfolio, which spans central lab testing to customized research support, positions them as a vital partner for oncologists and drug developers alike. Through its commitment to high-quality genomic data, Geneseeq is effectively bridging the gap between complex molecular diagnostics and clinical application, thereby accelerating the delivery of precision cancer care for patients suffering from solid tumors and hematologic malignancies.
How much funding has Geneseeq raised?
Geneseeq has raised a total of $127.9M across 3 funding rounds:
Series A
$4.8M
Series B
$9.1M
Series D
$114M
Series A (2014): $4.8M with participation from Beijing Beilu Pharmaceutical
Series B (2016): $9.1M led by Beijing D.Z Capital, Eastern Investment, and Beijing Beilu Pharmaceutical
Series D (2019): $114M supported by China Reform Holdings Corporation, Lilly Asia Ventures, and SoftBank China Venture Capital
Key Investors in Geneseeq
Lilly Asia Ventures
A leading biomedical venture capital firm with a global footprint, specializing in supporting entrepreneurs who develop breakthrough products to improve human health.
Beijing Beilu Pharmaceutical
A major pharmaceutical entity based in Beijing, focused on the development and distribution of medical products and therapeutic solutions.
Eastern Investment
A South Korean investment banking firm providing strategic financial backing to high-growth enterprises within the healthcare and technology sectors.
What's next for Geneseeq?
With the recent influx of capital, Geneseeq is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its local testing solutions and the deepening of its translational research partnerships. The company is expected to leverage these resources to enhance its proprietary data analytics engine, further refining its ability to provide predictive insights for drug development. As the precision oncology market continues to mature, Geneseeq's focus on operational efficiency and high-throughput genomic analysis will likely serve as a catalyst for sustained growth, enabling the firm to maintain its competitive edge in the global diagnostic landscape.
See full Geneseeq company page
